Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Kymera Therapeutics appoints Karen Weisbach as VP, people and culture » 07:18
07/29/21
07/29
07:18
07/29/21
07:18
KYMR

Kymera Therapeutics

$59.78 /

+1.79 (+3.09%)

, BLUE

Bluebird Bio

$25.99 /

+0.06 (+0.23%)

Kymera Therapeutics…

Kymera Therapeutics (KYMR) announced the appointments of Karen Weisbach, as Vice President, People and Culture, and Jolly Bhatia as Vice President, Quality. Prior to Kymera, she served in human resource leadership roles at bluebird bio (BLUE), including building and leading the global People Partner function responsible for driving talent and organizational strategies with an emphasis on employee engagement, development, and performance. Prior to Kymera, Bhatia served in quality leadership roles at X4 Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., and Genzyme Corporation.

ShowHide Related Items >><<
KYMR Kymera Therapeutics
$59.78 /

+1.79 (+3.09%)

BLUE Bluebird Bio
$25.99 /

+0.06 (+0.23%)

KYMR Kymera Therapeutics
$59.78 /

+1.79 (+3.09%)

07/07/21 Piper Sandler
Kymera data 'fundamentally de-risks' approach, says Piper Sandler
06/21/21 Piper Sandler
Kymera presents data showing KT-413 active in models, says Piper Sandler
05/20/21 UBS
Kymera Therapeutics initiated with a Buy at UBS
04/14/21 Berenberg
Kymera Therapeutics initiated with a Buy at Berenberg
BLUE Bluebird Bio
$25.99 /

+0.06 (+0.23%)

07/01/21 Berenberg
Bluebird Bio assumed at Hold from Buy at Berenberg
06/07/21 Citi
Gracell valuation provides attractive entry point, says Citi
04/21/21 BMO Capital
Bluebird Bio price target lowered to $31 from $35 at BMO Capital
04/20/21 Oppenheimer
Bluebird reimbursement talks not helped by lingering concerns, says Oppenheimer
KYMR Kymera Therapeutics
$59.78 /

+1.79 (+3.09%)

BLUE Bluebird Bio
$25.99 /

+0.06 (+0.23%)

  • 01
    Jul
  • 21
    Aug
KYMR Kymera Therapeutics
$59.78 /

+1.79 (+3.09%)

BLUE Bluebird Bio
$25.99 /

+0.06 (+0.23%)

KYMR Kymera Therapeutics
$59.78 /

+1.79 (+3.09%)

BLUE Bluebird Bio
$25.99 /

+0.06 (+0.23%)

Over a week ago
On The Fly
Fly Insider: Fast Acquisition, Airbnb among weeks notable trades » 14:18
07/12/21
07/12
14:18
07/12/21
14:18
KYMR

Kymera Therapeutics

$48.90 /

-3.94 (-7.46%)

, FST

Fast Acquisition

$13.30 /

-0.26 (-1.92%)

, CERE

Cerevel Therapeutics

$23.57 /

+0.11 (+0.47%)

, HCHC

HC2 Holdings

$3.91 /

+0.035 (+0.90%)

, GOOG

Alphabet

$2,598.70 /

+8.04 (+0.31%)

, FB

Facebook

$353.08 /

+2.76 (+0.79%)

, CVNA

Carvana

$324.41 /

+1.025 (+0.32%)

, ABNB

Airbnb

$146.75 /

-2.85 (-1.91%)

Welcome to "Fly Insider,"…

ShowHide Related Items >><<
KYMR Kymera Therapeutics
$48.90 /

-3.94 (-7.46%)

HCHC HC2 Holdings
$3.91 /

+0.035 (+0.90%)

GOOG Alphabet
$2,598.70 /

+8.04 (+0.31%)

FST Fast Acquisition
$13.30 /

-0.26 (-1.92%)

FB Facebook
$353.08 /

+2.76 (+0.79%)

CVNA Carvana
$324.41 /

+1.025 (+0.32%)

CERE Cerevel Therapeutics
$23.57 /

+0.11 (+0.47%)

ABNB Airbnb
$146.75 /

-2.85 (-1.91%)

KYMR Kymera Therapeutics
$48.90 /

-3.94 (-7.46%)

07/07/21 Piper Sandler
Kymera data 'fundamentally de-risks' approach, says Piper Sandler
06/21/21 Piper Sandler
Kymera presents data showing KT-413 active in models, says Piper Sandler
05/20/21 UBS
Kymera Therapeutics initiated with a Buy at UBS
04/14/21 Berenberg
Kymera Therapeutics initiated with a Buy at Berenberg
FST Fast Acquisition
$13.30 /

-0.26 (-1.92%)

CERE Cerevel Therapeutics
$23.57 /

+0.11 (+0.47%)

06/30/21 Citi
Karuna Therapeutics selloff brings buying opportunity, says Citi
06/30/21 Mizuho
Karuna selloff on Cerevel data 'appears overdone,' says Mizuho
06/18/21 Morgan Stanley
Cerevel Therapeutics initiated with an Overweight at Morgan Stanley
12/10/20 Goldman Sachs
Cerevel Therapeutics initiated with a Buy at Goldman Sachs
HCHC HC2 Holdings
$3.91 /

+0.035 (+0.90%)

12/11/20 B. Riley
HC2 Holdings price target lowered to $5 from $8.50 at B. Riley Securities
GOOG Alphabet
$2,598.70 /

+8.04 (+0.31%)

07/06/21 Roth Capital
Google-induced selloff in Digital Turbine an opportunity, says Roth Capital
07/06/21 Roth Capital
Zeta Global initiated with a Buy at Roth Capital
07/02/21 Craig-Hallum
Craig-Hallum says Magnite SpringServe deal more consequential than price implies
07/01/21 Roth Capital
Netlist price target raised to $6 on litigation clarity at Roth Capital
FB Facebook
$353.08 /

+2.76 (+0.79%)

07/06/21 Morgan Stanley
Arista Networks price target raised to $420 from $345 at Morgan Stanley
06/30/21 Argus
Facebook price target raised to $410 from $385 at Argus
06/28/21 Evercore ISI
Evercore ISI sees 'increasingly successful' VR product cycle at Facebook
CVNA Carvana
$324.41 /

+1.025 (+0.32%)

06/29/21
Fly Intel: Top five analyst downgrades
06/29/21 Piper Sandler
Shift price target raised to $16 from $14 at Piper Sandler
06/29/21 Piper Sandler
Carvana downgraded to Neutral from Overweight at Piper Sandler
06/25/21 Wells Fargo
Carvana price target raised to $360 from $340 at Wells Fargo
ABNB Airbnb
$146.75 /

-2.85 (-1.91%)

06/09/21 Loop Capital
Airbnb price target lowered to $195 from $240 at Loop Capital
05/26/21 RBC Capital
Airbnb initiated with an Outperform at RBC Capital
05/24/21 Truist
Airbnb's new flexiblity features 'particularly promising,' says Truist
05/21/21 Morgan Stanley
Airbnb price target lowered to $125 from $160 at Morgan Stanley
KYMR Kymera Therapeutics
$48.90 /

-3.94 (-7.46%)

HCHC HC2 Holdings
$3.91 /

+0.035 (+0.90%)

GOOG Alphabet
$2,598.70 /

+8.04 (+0.31%)

FB Facebook
$353.08 /

+2.76 (+0.79%)

CVNA Carvana
$324.41 /

+1.025 (+0.32%)

CERE Cerevel Therapeutics
$23.57 /

+0.11 (+0.47%)

ABNB Airbnb
$146.75 /

-2.85 (-1.91%)

  • 02
    Jul
  • 01
    Jul
  • 02
    Dec
  • 10
    Dec
  • 21
    Aug
GOOG Alphabet
$2,598.70 /

+8.04 (+0.31%)

FST Fast Acquisition
$13.30 /

-0.26 (-1.92%)

FB Facebook
$353.08 /

+2.76 (+0.79%)

CVNA Carvana
$324.41 /

+1.025 (+0.32%)

ABNB Airbnb
$146.75 /

-2.85 (-1.91%)

HCHC HC2 Holdings
$3.91 /

+0.035 (+0.90%)

GOOG Alphabet
$2,598.70 /

+8.04 (+0.31%)

FST Fast Acquisition
$13.30 /

-0.26 (-1.92%)

FB Facebook
$353.08 /

+2.76 (+0.79%)

CVNA Carvana
$324.41 /

+1.025 (+0.32%)

CERE Cerevel Therapeutics
$23.57 /

+0.11 (+0.47%)

ABNB Airbnb
$146.75 /

-2.85 (-1.91%)

KYMR Kymera Therapeutics
$48.90 /

-3.94 (-7.46%)

GOOG Alphabet
$2,598.70 /

+8.04 (+0.31%)

FST Fast Acquisition
$13.30 /

-0.26 (-1.92%)

FB Facebook
$353.08 /

+2.76 (+0.79%)

CVNA Carvana
$324.41 /

+1.025 (+0.32%)

CERE Cerevel Therapeutics
$23.57 /

+0.11 (+0.47%)

ABNB Airbnb
$146.75 /

-2.85 (-1.91%)

Hot Stocks
Kymera Therapeutics presents new preclinical data on STAT3 degraders » 08:21
07/12/21
07/12
08:21
07/12/21
08:21
KYMR

Kymera Therapeutics

$52.75 /

+2.835 (+5.68%)

Kymera Therapeutics…

Kymera Therapeutics announced new preclinical data demonstrating the therapeutic potential of its STAT3 degraders for the treatment of peripheral T-cell lymphoma with aberrant STAT3 activation. Kymera's STAT3 degraders have been shown to strongly repress cancer cell growth in preclinical models of STAT3-dependent heme malignancies, including subtypes of PTCL such as ALK-positive anaplastic large cell lymphoma. Kymera's lead STAT3 degrader candidate, KT-333, is currently in preclinical development and Kymera plans to submit an Investigational New Drug Application to the U.S. Food and Drug Administration in the fourth quarter of 2021 and, if cleared, initiate a Phase 1 clinical trial in patients thereafter. Data highlights include: Kymera has discovered a series of potent and selective STAT3 degraders with activity against both wild-type and clinically-relevant mutant forms of STAT3. STAT3 degraders result in growth arrest and increased cell death of ALK-positive ALCL, as well as STAT3-mutant NK/T-cell lymphoma and ALK-negative ALCL cell lines, both in vitro and in vivo, including complete tumor regressions in vivo in ALK-positive ALCL with IV weekly dosing. Pathway analyses in STAT3 degrader-treated ALK-positive ALCL show down-regulation of STAT3-regulated processes including cytokine responses and consistent down-regulation of cell cycle signatures and up-regulation of immune pathways, suggesting modulation of tumor cell-intrinsic processes and the potential to regulate cell-cell interactions in the tumor microenvironment. A subset of transcriptional responses to STAT3 degrader is conserved between ALK-positive ALCL and STAT3 mutant NK/T-cell lymphoma cell lines.

ShowHide Related Items >><<
KYMR Kymera Therapeutics
$52.75 /

+2.835 (+5.68%)

KYMR Kymera Therapeutics
$52.75 /

+2.835 (+5.68%)

07/07/21 Piper Sandler
Kymera data 'fundamentally de-risks' approach, says Piper Sandler
06/21/21 Piper Sandler
Kymera presents data showing KT-413 active in models, says Piper Sandler
05/20/21 UBS
Kymera Therapeutics initiated with a Buy at UBS
04/14/21 Berenberg
Kymera Therapeutics initiated with a Buy at Berenberg
KYMR Kymera Therapeutics
$52.75 /

+2.835 (+5.68%)

  • 01
    Jul
  • 21
    Aug
KYMR Kymera Therapeutics
$52.75 /

+2.835 (+5.68%)

Recommendations
Kymera data 'fundamentally de-risks' approach, says Piper Sandler » 04:53
07/07/21
07/07
04:53
07/07/21
04:53
KYMR

Kymera Therapeutics

$54.17 /

-2.205 (-3.91%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff reiterates an Overweight rating on Kymera Therapeutics with an $80 price target after the company last week reported first-ever human data on IRAK4 degrader KT-474. The analyst believes this "safe, potent IRAK4 knock-down fundamentally de-risks" Kymera's protein degradation approach. The analyst adds that the company strengthened its balance sheet through a secondary offering.

ShowHide Related Items >><<
KYMR Kymera Therapeutics
$54.17 /

-2.205 (-3.91%)

KYMR Kymera Therapeutics
$54.17 /

-2.205 (-3.91%)

06/21/21 Piper Sandler
Kymera presents data showing KT-413 active in models, says Piper Sandler
05/20/21 UBS
Kymera Therapeutics initiated with a Buy at UBS
04/14/21 Berenberg
Kymera Therapeutics initiated with a Buy at Berenberg
04/12/21 Piper Sandler
Piper would be buyer of Kymera Therapeutics amid pullback
KYMR Kymera Therapeutics
$54.17 /

-2.205 (-3.91%)

  • 01
    Jul
  • 21
    Aug
KYMR Kymera Therapeutics
$54.17 /

-2.205 (-3.91%)

Over a month ago
Syndicate
Kymera Therapeutics 4.755M share Secondary priced at $47.00 » 06:06
07/01/21
07/01
06:06
07/01/21
06:06
KYMR

Kymera Therapeutics

$48.51 /

+5.86 (+13.74%)

The deal size was…

The deal size was increased to 4.755M shares from 4.0M. Morgan Stanley, JPMorgan, Cowen and Guggenheim are acting as joint book running managers for the offering.

ShowHide Related Items >><<
KYMR Kymera Therapeutics
$48.51 /

+5.86 (+13.74%)

KYMR Kymera Therapeutics
$48.51 /

+5.86 (+13.74%)

06/21/21 Piper Sandler
Kymera presents data showing KT-413 active in models, says Piper Sandler
05/20/21 UBS
Kymera Therapeutics initiated with a Buy at UBS
04/14/21 Berenberg
Kymera Therapeutics initiated with a Buy at Berenberg
04/12/21 Piper Sandler
Piper would be buyer of Kymera Therapeutics amid pullback
KYMR Kymera Therapeutics
$48.51 /

+5.86 (+13.74%)

  • 01
    Jul
  • 21
    Aug
KYMR Kymera Therapeutics
$48.51 /

+5.86 (+13.74%)

Syndicate
Kymera Therapeutics files to sell 4M shares of common stock » 16:33
06/28/21
06/28
16:33
06/28/21
16:33
KYMR

Kymera Therapeutics

$47.20 /

+2.74 (+6.16%)

Managers include Morgan…

Managers include Morgan Stanley, J.P. Morgan, Cowen, and Guggenheim Securities.

ShowHide Related Items >><<
KYMR Kymera Therapeutics
$47.20 /

+2.74 (+6.16%)

KYMR Kymera Therapeutics
$47.20 /

+2.74 (+6.16%)

06/21/21 Piper Sandler
Kymera presents data showing KT-413 active in models, says Piper Sandler
05/20/21 UBS
Kymera Therapeutics initiated with a Buy at UBS
04/14/21 Berenberg
Kymera Therapeutics initiated with a Buy at Berenberg
04/12/21 Piper Sandler
Piper would be buyer of Kymera Therapeutics amid pullback
KYMR Kymera Therapeutics
$47.20 /

+2.74 (+6.16%)

  • 21
    Aug
KYMR Kymera Therapeutics
$47.20 /

+2.74 (+6.16%)

Hot Stocks
Kymera Therapeutics reports 'positive' results from Phase 1 trial of KT-474 » 06:07
06/28/21
06/28
06:07
06/28/21
06:07
KYMR

Kymera Therapeutics

$44.46 /

+0.09 (+0.20%)

Kymera Therapeutics…

Kymera Therapeutics announced positive interim results from the Single Ascending Dose portion of the Phase 1 clinical trial of KT-474, demonstrating the first degrader proof-of-mechanism in targeted protein degradation in a randomized, placebo-controlled healthy volunteer study. KT-474 has achieved and exceeded the Phase 1 target degradation of 85% within the SAD portion of the Phase 1 trial dosed to date, with profound IRAK4 degradation after a single oral dose that lasted for at least six days at all dose levels. The partial clinical hold on the Multiple Ascending Dose portion of the Phase 1 trial of KT-474 has been lifted following review by the U.S. FDA of interim safety, pharmacokinetic and pharmacodynamic data from the first three cohorts of the SAD healthy volunteer portion of the Phase 1 study. In the SAD portion of the trial, healthy volunteer subjects are randomized 6:2 to either a single oral dose of KT-474 or placebo. Interim data, which also include results from the fourth cohort of the trial, showed dose and time-dependent IRAK4 degradation following single oral KT-474 dose administration. IRAK4 levels were measured in peripheral blood mononuclear cells (PBMC) using mass spectrometry. Following a single KT-474 oral dose, IRAK4 reduction was observed as early as eight hours post-dose, reached maximal reduction at 48 to 72 hours, and was sustained for at least six days with subsequent recovery towards pre-treatment baseline across all dose groups. In the fourth cohort, following a single 300 mg dose of KT-474, median IRAK4 reduction from baseline at 48 hours was 90% compared to a 16% increase in the placebo group, with maximum IRAK4 reduction of 94%, demonstrating proof-of-mechanism for KT-474. KT-474, to date, has demonstrated oral bioavailability, predictable and dose-dependent plasma exposures, and a half-life supportive of oral daily dosing. No treatment-related adverse events have been observed to date.

ShowHide Related Items >><<
KYMR Kymera Therapeutics
$44.46 /

+0.09 (+0.20%)

KYMR Kymera Therapeutics
$44.46 /

+0.09 (+0.20%)

06/21/21 Piper Sandler
Kymera presents data showing KT-413 active in models, says Piper Sandler
05/20/21 UBS
Kymera Therapeutics initiated with a Buy at UBS
04/14/21 Berenberg
Kymera Therapeutics initiated with a Buy at Berenberg
04/12/21 Piper Sandler
Piper would be buyer of Kymera Therapeutics amid pullback
KYMR Kymera Therapeutics
$44.46 /

+0.09 (+0.20%)

  • 21
    Aug
KYMR Kymera Therapeutics
$44.46 /

+0.09 (+0.20%)

Hot Stocks
Kymera Therapeutics appoints Elaine Caughey as chief business officer » 16:05
06/21/21
06/21
16:05
06/21/21
16:05
KYMR

Kymera Therapeutics

$47.10 /

-0.09 (-0.19%)

Kymera Therapeutics…

Kymera Therapeutics announced the appointment of Elaine Caughey as chief business officer, or CBO. Caughey joins Kymera with over 20 years of experience in the biotechnology industry, including leadership roles in corporate development, business and commercial operations, new product strategy, and investing. Caughey joins Kymera with over 20 years of experience in the biotechnology industry. Prior to Kymera, she led business development, strategy and operations as the CBO at Cygnal Therapeutics.

ShowHide Related Items >><<
KYMR Kymera Therapeutics
$47.10 /

-0.09 (-0.19%)

KYMR Kymera Therapeutics
$47.10 /

-0.09 (-0.19%)

06/21/21 Piper Sandler
Kymera presents data showing KT-413 active in models, says Piper Sandler
05/20/21 UBS
Kymera Therapeutics initiated with a Buy at UBS
04/14/21 Berenberg
Kymera Therapeutics initiated with a Buy at Berenberg
04/12/21 Piper Sandler
Piper would be buyer of Kymera Therapeutics amid pullback
KYMR Kymera Therapeutics
$47.10 /

-0.09 (-0.19%)

  • 21
    Aug
KYMR Kymera Therapeutics
$47.10 /

-0.09 (-0.19%)

Recommendations
Kymera presents data showing KT-413 active in models, says Piper Sandler » 13:48
06/21/21
06/21
13:48
06/21/21
13:48
KYMR

Kymera Therapeutics

$48.00 /

+0.81 (+1.72%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff reiterated an Overweight rating and $80 price target on Kymera Therapeutics. Kymera presented preclinical data on IRAKIMiD degrader KT-413 at the virtual International Conference on Malignant Lymphoma meeting showing that KT-413 was active in MYD88-mutant mouse and DLBCL patient-derived models, and was additive to rituximab, ibrutinib and venetoclax, Tenthoff tells investors in a research note. Kymera intends to file an IND for KT-333 in solid tumors in 4Q21, the analyst adds.

ShowHide Related Items >><<
KYMR Kymera Therapeutics
$48.00 /

+0.81 (+1.72%)

KYMR Kymera Therapeutics
$48.00 /

+0.81 (+1.72%)

05/20/21 UBS
Kymera Therapeutics initiated with a Buy at UBS
04/14/21 Berenberg
Kymera Therapeutics initiated with a Buy at Berenberg
04/12/21 Piper Sandler
Piper would be buyer of Kymera Therapeutics amid pullback
03/02/21 Piper Sandler
Kymera Therapeutics plans to file two INDs in 2H21, says Piper Sandler
KYMR Kymera Therapeutics
$48.00 /

+0.81 (+1.72%)

  • 21
    Aug
KYMR Kymera Therapeutics
$48.00 /

+0.81 (+1.72%)

Hot Stocks
Kymera Therapeutics presents preclinical data for KT-413 » 08:38
06/21/21
06/21
08:38
06/21/21
08:38
KYMR

Kymera Therapeutics

$47.19 /

-0.58 (-1.21%)

Kymera Therapeutics…

Kymera Therapeutics announced new preclinical data on its IRAKIMiD degrader KT-413's potential as both a monotherapy and in combination with other anticancer agents. The data were featured in an oral presentation at the 16th Annual International Conference on Malignant Lymphoma virtual meeting, taking place from June 18 - 22, 2021. IRAKIMiDs are novel heterobifunctional degraders designed to degrade both IRAK4 and IMiD substrates, including Ikaros and Aiolos, with a single small molecule. IRAKIMiDs synergistically target both the MYD88-NFkB and IRF4-Type 1 interferon pathways to enhance and broaden antitumor activity in MYD88-mutant diffuse large B-cell lymphoma. KT-413 is being developed initially for the treatment of relapsed/refractory MYD88-mutant DLBCL, with the potential to expand into other MYD88-mutant indications and IL-1R/NFkB-driven malignancies. KT-413 is currently in preclinical development and Kymera plans to submit an Investigational New Drug Application to the U.S. Food and Drug Administration in the second half of 2021 and, if cleared, initiate a Phase 1 clinical trial in patients thereafter. Data highlights include: In the OCI-Ly10 MYD88-mutant mouse xenograft model, intermittent dosing of KT-413 in vivo induced deep and sustained antitumor activity, including complete or partial regressions, that was superior to the clinically active IRAK4 kinase inhibitor CA-4948 or the latest generation IMiD CC-220. KT-413 showed strong tumor growth inhibition in multiple MYD88-mutant DLBCL patient-derived xenograft in vivo models. KT-413 showed strongly additive antitumor activity in combination with the anti-CD20 monoclonal antibody rituximab, the BTK inhibitor ibrutinib, or the BCL-2 inhibitor venetoclax, in MYD88-mutantOCI-Ly10 xenografts in vivo, suggesting the potential for therapeutically relevant drug combinations in MYD88-mutant DLBCL.

ShowHide Related Items >><<
KYMR Kymera Therapeutics
$47.19 /

-0.58 (-1.21%)

KYMR Kymera Therapeutics
$47.19 /

-0.58 (-1.21%)

05/20/21 UBS
Kymera Therapeutics initiated with a Buy at UBS
04/14/21 Berenberg
Kymera Therapeutics initiated with a Buy at Berenberg
04/12/21 Piper Sandler
Piper would be buyer of Kymera Therapeutics amid pullback
03/02/21 Piper Sandler
Kymera Therapeutics plans to file two INDs in 2H21, says Piper Sandler
KYMR Kymera Therapeutics
$47.19 /

-0.58 (-1.21%)

  • 21
    Aug
KYMR Kymera Therapeutics
$47.19 /

-0.58 (-1.21%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.